Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study

Despite multimodal treatment with surgery and radiochemotherapy, the prognosis of glioblastoma remains poor, and practically all glioblastomas relapse. To date, no standard treatment exists for recurrent glioblastoma patients and traditional therapies have showed limited efficacy. Regorafenib is an...

Full description

Bibliographic Details
Main Authors: Giuseppe Lombardi, Mario Caccese, Marta Padovan, Giulia Cerretti, Giovanna Pintacuda, Renzo Manara, Francesca Di Sarra, Vittorina Zagonel
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
regorafenib
glioblastoma
brain tumors
glioma
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/13/18/4731

Internet

https://www.mdpi.com/2072-6694/13/18/4731

Similar Items